STOCK TITAN
  1. Home
  2. Sec-filings
  3. LEGN
  4. [Form 3] Legend Biotech Corp Initial Statement of Beneficial Ownership

Legend Biotech (LEGN) interim CEO discloses 30,234-share ownership stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Legend Biotech Corp’s interim CEO, Alan Bash, reports initial beneficial ownership of 30,234 ordinary shares, held directly. This amount includes 13,092 restricted share units (RSUs) for which performance criteria have been satisfied and that are scheduled to vest on 12/20/2026, subject to his continued service. Each RSU represents a contingent right to receive one ordinary share, and each American Depositary Share represents two ordinary shares.

Positive

  • None.

Negative

  • None.
Insider BASH ALAN
Role Interim CEO
Type Security Shares Price Value
holding Ordinary Shares F1, F2 -- -- --
Holdings After Transaction: Ordinary Shares — 30,234 shares (Direct)
Footnotes (2)
  1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
  2. F2. Includes 13,092 restritcted share units (the "RSUs") for which the performance criteria was previously determined to have been satisfied and which will vest on 12/20/2026, subject to the Reporting Person's continued service to the Issuer on such vesting date. Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement.
Ordinary shares beneficially owned 30,234 ordinary shares Direct holdings reported by interim CEO Alan Bash following the reported holding entry
Restricted share units included 13,092 RSUs RSUs with satisfied performance criteria that are included within the reported beneficial ownership
RSU vesting date 12/20/2026 Scheduled vesting date for the 13,092 restricted share units, subject to continued service
ADS to ordinary share ratio 1 ADS = 2 ordinary shares Each American Depositary Share represents two ordinary shares of Legend Biotech
American Depositary Shares financial
"The Ordinary Shares of the Issuer may be represented by American Depositary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
restricted share units financial
"Includes 13,092 restricted share units (the "RSUs") for which the performance criteria"
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
contingent right financial
"Each RSU represents a contingent right to receive one ordinary share of the Issuer"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What does Legend Biotech (LEGN) disclose about Alan Bash’s shareholdings?
Legend Biotech’s interim CEO Alan Bash reports beneficial ownership of 30,234 ordinary shares, held directly. This total includes both currently held shares and restricted share units tied to future vesting.

How many RSUs does Alan Bash hold in Legend Biotech (LEGN)?
Alan Bash holds 13,092 restricted share units (RSUs). Performance criteria for these RSUs have been satisfied, and they are scheduled to vest on 12/20/2026, assuming his continued service with Legend Biotech.

When do Alan Bash’s RSUs in Legend Biotech (LEGN) vest?
The 13,092 RSUs reported by interim CEO Alan Bash are scheduled to vest on 12/20/2026. Vesting is contingent on his continued service to Legend Biotech through that date.

What is the ADS to ordinary share ratio for Legend Biotech (LEGN)?
Legend Biotech states that each American Depositary Share (ADS) represents two ordinary shares. Ordinary shares reported in the ownership table may be represented by ADSs using this 2-to-1 ratio.

Does the Form 3 for Legend Biotech (LEGN) show recent insider buying or selling?
The Form 3 from interim CEO Alan Bash reports holdings of ordinary shares and RSUs but does not show any new purchase or sale transactions. It serves as an initial ownership statement.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
BASH ALAN
(Last)(First)(Middle)
C/O LEGEND BIOTECH CORP
2101 COTTONTAIL LANE
(Street)
SOMERSET NEW JERSEY 08873
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
07/24/2026		3. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Interim CEO
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)30,234(2)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
2. Includes 13,092 restritcted share units (the "RSUs") for which the performance criteria was previously determined to have been satisfied and which will vest on 12/20/2026, subject to the Reporting Person's continued service to the Issuer on such vesting date. Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Robert Staloff, Attorney-in-Fact08/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR